Is Protalix Biotherapeutics Inc (PLX) overvalued? · P/E 31, rev $53.4M
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
This page asks whether Protalix Biotherapeutics Inc (PLX) looks expensive on cached numbers — not a short thesis.
Latest reported PLX revenue for 2024-12-31 was $53.4M. Net income was $2.9M. Revenue was down 18.5% from 2023-12-31 to 2024-12-31. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
PLX currently screens at market cap $122.6M and trailing P/E 30.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PLX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PLX stock page for the full model, not this heading.
Not investment advice.